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Background
Long-term efficacy of antiretrovirals (ARV) may be
blunted by cumulative toxicity. Tenofovir (TDF) is the
most widely prescribed antiretroviral agent, and the pre-
ferred choice for most drug-naïve subjects. Although it
shows a safe metabolic profile, much attention has been
focused on kidney disturbances and bone demineraliza-
tion. Since glomerular function is infrequently affected in
patients treated with TDF, herein we report the results of
extensive exam of the kidney tubular function.
Methods
Prospective cross-sectional study in three groups of HIV
patients, based on prior ARV experience: G1, ARV naive;
G2, under ARV but never exposed to TDF; and G3, cur-
rently under TDF. Glomerular function was assessed using
creatinine clearance (CrCl). Tubular function was exam-
ined using three major (non-diabetic glycosuria, ami-
noaciduria, and fractional tubular resorption of
phosphate) and two minor criteria (fractional excretion of
uric acid and β2 microglobulinuria). Variables were meas-
ured in plasma and 24-hr urine analysis. Tubular dysfunc-
tion was defined as ≥2 abnormal parameters (including
≥1 major).
Summary of results
A total of 284 consecutive HIV patients were analyzed: 81
in G1, 49 in G2 and 154 in G3. Mean ARV exposure was
59 and 55 months in G2 and G3, respectively; mean TDF
exposure in G3 was 36 months. The proportion of
patients with tubular dysfunction was 12% in G1, 6% in
G2 and 22% in G3 (p = 0.01 for G2 vs. G3). The propor-
tion of HIV patients on ARV therapy developing tubular
dysfunction over time is depicted in Figure 1.
Conclusion
Treatment with TDF is associated with an increased risk
over time of kidney tubular damage in the absence of sig-
nificant glomerular impairment. The long-term conse-
quences of abnormal tubular dysfunction in patients on
TDF warrant close examination.
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